These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36480286)

  • 21. Compressive Optic Neuropathy in Thyroid Eye Disease.
    Thyparampil P; Yen MT
    Int Ophthalmol Clin; 2016; 56(1):51-67. PubMed ID: 26626932
    [No Abstract]   [Full Text] [Related]  

  • 22. Fourth International Thyroid Eye Disease Symposium: Introduction.
    Uddin JM
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S1-S2. PubMed ID: 29985834
    [No Abstract]   [Full Text] [Related]  

  • 23. [Graves' ophthalmopathy].
    Eckstein A; Dekowski D; Führer-Sakel D; Berchner-Pfannschmidt U; Esser J
    Ophthalmologe; 2016 Apr; 113(4):349-64; quiz 465-6. PubMed ID: 27059986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Commentary: Multidisciplinary team approach to tackle thyroid eye disease.
    Mahesh L
    Indian J Ophthalmol; 2020 Aug; 68(8):1615-1616. PubMed ID: 32709790
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Graves' ophthalmopathy.
    González-García A; Sales-Sanz M
    Med Clin (Barc); 2021 Feb; 156(4):180-186. PubMed ID: 33069387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroid-Associated Orbitopathy: Management and Treatment.
    Hennein L; Robbins SL
    J Binocul Vis Ocul Motil; 2022; 72(1):32-46. PubMed ID: 34874796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical practice. Graves' ophthalmopathy.
    Bartalena L; Tanda ML
    N Engl J Med; 2009 Mar; 360(10):994-1001. PubMed ID: 19264688
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of Graves' disease in patients with thyroid eye disease].
    Sviridenko NY; Sheremeta MS; Belovalova IM; Melnichenko GA
    Vestn Oftalmol; 2021; 137(6):128-135. PubMed ID: 34965078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid Eye Disease.
    Szelog J; Swanson H; Sniegowski MC; Lyon DB
    Mo Med; 2022; 119(4):343-350. PubMed ID: 36118816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Graves' ophthalmopathy from the internist's perspective].
    Laubner K; Weber WA; Seufert J
    Ophthalmologe; 2011 May; 108(5):410-6. PubMed ID: 21590351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Graves' ophthalmopathy].
    Hiromatsu Y
    Nihon Rinsho; 2006 May; Suppl 1():307-10. PubMed ID: 16776151
    [No Abstract]   [Full Text] [Related]  

  • 32. Thyroid eye disease for the primary care physician.
    Phelps PO; Williams K
    Dis Mon; 2014 Jun; 60(6):292-8. PubMed ID: 24906675
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of Graves ophthalmopathy - 2022 update.
    Jiskra J
    Cas Lek Cesk; 2022; 161(5):198-206. PubMed ID: 36443100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
    Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR
    Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymmetric Graves' Orbitopathy.
    Panagiotou G; Perros P
    Front Endocrinol (Lausanne); 2020; 11():611845. PubMed ID: 33391188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Basedow's ophthalmopathy].
    Raynaud L; Benois A; Lafond P
    Rev Prat; 2008 May; 58(10):1060. PubMed ID: 18652402
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical perspectives of thyroid eye disease.
    Durairaj VD
    Am J Med; 2006 Dec; 119(12):1027-8. PubMed ID: 17145242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Graves' orbitopathy: diagnosis, epidemiology and treatments].
    Lun AY; Le Bras M; Scharbarg E; Morcel P; Hadjadj S; Lebranchu P; Drui D
    Rev Med Interne; 2022 Apr; 43(4):242-251. PubMed ID: 35221112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Management of Graves' orbitopathy. Comments on the EUGOGO consensus statement].
    Bednarczuk T; Bar-Andziak E; Hubalewska-Dydejczyk A; Waligórska A; Górska M; Myśliwiec J; Jarzab B; Karczmarzyk R; Zawadzka A; Garmol D; Kecik D; Królicki L; Plazińska MT; Krzeski A; Krzyzanowska-Swiniarska B; Lewiński A; Milewicz A; Daroszewski J; Placzkiewicz-Jankowska E; Pilarska K; Skórski M; Wiechno W; Sowiński J; Syrenicz A; Szafilk J; Wanyura H; Zgliczński W; Jastrzebska H; Nauman J
    Endokrynol Pol; 2009; 60(4):312-30. PubMed ID: 19753546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.